Screener
BOUT vs XTAP
Innovator IBD Breakout Opportunities ETF vs Innovator U.S. Equity Accelerated Plus ETF – April
Key differences
- Over the last 3 years, XTAP has delivered higher annualized returns.
Side-by-side comparison
| BOUT | XTAP | |
|---|---|---|
| Annual cost (TER) | 0.80% | 0.79% |
| Fund size (AUM) | $16M | $22M |
| Since | 2018 | 2021 |
| Dividend yield | 0.28% | 0.00% |
| Asset class | alternative | alternative |
| Region | north america | north america |
| Strategy | structured outcome | structured outcome |
| CAGR 1Y | +34.2% | +22.3% |
| CAGR 3Y | +16.2% | +18.7% |
| CAGR 5Y | +7.6% | +11.3% |
| Sharpe 3Y | 0.70 | 1.34 |
| Volatility 1Y | 20.64% | 4.91% |
| Max drawdown | -36.75% | -22.13% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to BOUT and XTAP
Explore further